Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Europe Breast Cancer Market

ID: MRFR/HC/14663-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Europe Breast Cancer Market Research Report Information By Therapy (Targeted Therapy {Adotrastuzumab Emtansine, Everolimus, Trastuzumab, Abemaciclib, Ribociclib, Palbocicib, Pertuzumab, Olaparib, and Others}, Hormonal Therapy {Selective Estrogen Receptor Modulators, Estrogen Receptor Downregulators, Aromatase Inhibitors, Chemotherapy [Epothiones, Taxanes, Alkylating agents, Anthracyclines, Anti-metabolites], and Immunotherapy}, Surgery & Radiation Therapy, and Biologic Therapy), By Cancer Type (Hormone Receptor, and HER2+), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others) –and Europe Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Europe Breast Cancer Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Million)
      1. 4.1.1 Chemotherapy
      2. 4.1.2 Radiation Therapy
      3. 4.1.3 Hormonal Therapy
      4. 4.1.4 Targeted Therapy
    2. 4.2 Healthcare, BY Stage of Cancer (USD Million)
      1. 4.2.1 Stage 0
      2. 4.2.2 Stage I
      3. 4.2.3 Stage II
      4. 4.2.4 Stage III
      5. 4.2.5 Stage IV
    3. 4.3 Healthcare, BY Diagnosis Method (USD Million)
      1. 4.3.1 Mammography
      2. 4.3.2 Ultrasound
      3. 4.3.3 Biopsy
      4. 4.3.4 Magnetic Resonance Imaging
    4. 4.4 Healthcare, BY Patient Demographics (USD Million)
      1. 4.4.1 Age Group
      2. 4.4.2 Gender
      3. 4.4.3 Socioeconomic Status
      4. 4.4.4 Genetic Predisposition
    5. 4.5 Healthcare, BY Healthcare Setting (USD Million)
      1. 4.5.1 Hospital
      2. 4.5.2 Outpatient Clinic
      3. 4.5.3 Home Care
      4. 4.5.4 Specialized Cancer Center
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bristol-Myers Squibb (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 GSK (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eli Lilly (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 EUROPE MARKET ANALYSIS BY STAGE OF CANCER
    4. 6.4 EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
    5. 6.5 EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 EUROPE MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million)
      2. 7.2.2 BY STAGE OF CANCER, 2026-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS METHOD, 2026-2035 (USD Million)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
      5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Europe Healthcare Market Segmentation

Healthcare By Treatment Type (USD Million, 2026-2035)

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Targeted Therapy

Healthcare By Stage of Cancer (USD Million, 2026-2035)

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Healthcare By Diagnosis Method (USD Million, 2026-2035)

  • Mammography
  • Ultrasound
  • Biopsy
  • Magnetic Resonance Imaging

Healthcare By Patient Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status
  • Genetic Predisposition

Healthcare By Healthcare Setting (USD Million, 2026-2035)

  • Hospital
  • Outpatient Clinic
  • Home Care
  • Specialized Cancer Center

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓